Dow Inc. (DOW)

Revenue has declined ~5-8% as polyethylene and isocyanate pricing falls. Dow is underperforming diversified chemical peers (EMN, DD, LYB) who have specialty segments to offset commodity weakness. In a commodity business, revenue growth is dictated by pricing cycles, and Dow is on the wrong side of this one.

Dow is the world's largest polyethylene producer and a top-3 player in most commodity chemical categories. Share is stable but irrelevant when the entire industry is oversupplied. Chinese and Middle Eastern capacity additions have expanded the global supply base, diluting everyone's effective share. Dow's Gulf Coast cost position provides structural advantage but doesn't prevent margin compression.

Near-zero pricing power in commodity chemicals. Polyethylene, MDI, and silicones are benchmarked commodities where Dow is a price-taker. The only pricing lever is cost position (feedstock advantage) — Dow can maintain margin relative to higher-cost producers, but absolute pricing follows global supply-demand dynamics that Dow cannot influence.

Limited product innovation in commodity chemicals. Dow's sustainability initiatives (circular plastics, lower-carbon products) are directionally positive but generate minimal revenue premium today. The Path2Zero facility in Alberta is a long-term differentiation play but won't contribute meaningfully until 2028-2030.

Minimal switching costs. Commodity polyethylene and chemicals are fungible — customers routinely switch between Dow, LyondellBasell, and ExxonChemical based on price and availability. Some specialty grades have modest qualification requirements, but the vast majority of Dow's revenue comes from products where switching is trivial.

No meaningful network effects in commodity chemicals. Scale provides procurement and logistics advantages but these are cost-of-scale benefits, not network effects. Dow's product doesn't become more valuable with more users.

Chemical manufacturing has high regulatory barriers (EPA, environmental permits) that limit new domestic entrants. Dow's existing permits for Gulf Coast facilities are valuable. However, the competitive threat comes from overseas where regulatory barriers are lower. IP protection in commodity chemicals is limited — process patents have narrow windows.

Chemical plants cost $2-5B to build, creating real barriers to entry. Dow's integrated production sites provide cost advantages through backward integration to feedstock. But this same capital intensity means Dow must continuously invest to maintain assets, and the Path2Zero retrofit adds $6B+ in capital requirements over the next 5 years.

FY2026 EPS estimates have been cut ~15-20% over the past year as the commodity trough persists longer than expected. Consensus is below $3.00 EPS — less than half of cycle-peak earnings. Revisions are still trending negative. The earnings trajectory is fundamentally broken until commodity pricing improves.

The narrative is grim: 'commodity trough,' 'China overcapacity,' 'dividend at risk.' Dow's 5%+ dividend yield looks like a trap rather than a reward. The Path2Zero story generates some ESG interest but the market is focused on near-term earnings pain. Short interest has increased. Dow is a show-me story with nothing to show.

CEO Jim Fitterling has been transparent about the challenging environment, but the Path2Zero capital allocation decision is controversial — investing $6B+ during an earnings trough strains the balance sheet and may force a dividend cut. The market would prefer capital preservation over growth spending in this environment. Management is playing the long game in a market that cares about the next quarter.